Jorge Cortes, MD, Georgia Cancer Center, Augusta University, Augusta, GA, discusses the ASC4FIRST study (NCT04971226), comparing asciminib to imatinib and other second-generation tyrosine kinase inhibitors (TKIs) in the frontline treatment of chronic myeloid leukemia (CML). There was a significant benefit in the rate of major molecular response (MMR) at 48 weeks in those treated with asciminib, as well as an improved safety profile. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
